Login to Your Account

Aphton's Insegia Misses In Pancreatic Cancer Phase III

By Karen Pihl-Carey

Wednesday, February 16, 2005
Aphton Corp.'s stock fell more than 45 percent Tuesday following news that its lead pancreatic cancer drug, Insegia, failed to meet the primary endpoint in a Phase III trial. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription